Abstract

Cancer genomes have been explored from the early 2000s through massive exome sequencing efforts, leading to the publication of The Cancer Genome Atlas in 2013. Sequencing techniques have been developed alongside this project and have allowed scientists to bypass the limitation of costs for whole‐genome sequencing (WGS) of single specimens by developing more accurate and extensive cancer sequencing projects, such as deep sequencing of whole genomes and transcriptomic analysis. The Pan‐Cancer Analysis of Whole Genomes recently published WGS data from more than 2600 human cancers together with almost 1200 related transcriptomes. The application of WGS on a large database allowed, for the first time in history, a global analysis of features such as molecular signatures, large structural variations and noncoding regions of the genome, as well as the evaluation of RNA alterations in the absence of underlying DNA mutations. The vast amount of data generated still needs to be thoroughly deciphered, and the advent of machine‐learning approaches will be the next step towards the generation of personalized approaches for cancer medicine. The present manuscript wants to give a broad perspective on some of the biological evidence derived from the largest sequencing attempts on human cancers so far, discussing advantages and limitations of this approach and its power in the era of machine learning.

Highlights

  • Cancer genomes have been explored from the early 2000s through massive exome sequencing efforts, leading to the publication of The Cancer Genome Atlas in 2013

  • Sequencing techniques have been developed alongside this project and have allowed scientists to bypass the limitation of costs for whole-genome sequencing (WGS) of single specimens by developing more accurate and extensive cancer sequencing projects, such as deep sequencing of whole genomes and transcriptomic analysis

  • Molecular Oncology published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies

Read more

Summary

Global genomic profiling: from the TCGA to the IGCG-ARGO projects

As a result of the continuous advances in DNA sequencing techniques and a massive reduction of the associated costs, scientists have been able to move from a classic mechanistic approach, in which a single gene or a set of a few genes were studied to elucidate their roles in cancer development, to global observational analyses This step has led to the evaluation of the genomic alterations in cancers as a global network of molecular events, generating a huge amount of data from single cancer specimens [1]. In February 2020, the PCAWG published a large part of the results obtained by comparing almost 2700 cancer genomes to their existing normal matching controls, together with almost 1200 transcriptomes (Fig. 1B) [48] This huge effort allowed scientists to explore, for the first time and in a systematic way, noncoding regions of cancer genomes, and to postulate their role in cancer evolution. The ICGC is developing the ARGO (Accelerating Research in Genomic Oncology)–IGCG project, aimed at coupling more than 80 000 wholecancer genomes to more accurate clinical data from patients (Fig. 1C) [50], but many more projects are starting all around the world [51]

Mutational signatures from WGS
Application of WGS on large cancer specimen databases
Large structural variations from WGS
Molecular timing of cancer evolution
RNA dysregulation in cancer
Capturing genomic alterations during cancer evolution
Executable cancer models: successes and challenges
Findings
Conflict of interest
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call